Kisunla (donanemab-azbt) is a biologic therapy indicated for adults with early symptomatic Alzheimer’s disease (mild cognitive impairment or mild dementia due to Alzheimer’s). It works by targeting amyloid-β plaques in the brain to help slow disease progression.
Kisunla is an intravenous monoclonal antibody designed to bind to and facilitate the removal of amyloid-β plaques from the brain. It is FDA-approved for adults with early symptomatic Alzheimer’s disease, specifically those with mild cognitive impairment (MCI) or mild dementia, in whom amyloid pathology has been confirmed.
Kisunla binds to aggregated amyloid-β in brain plaques, marking them for clearance by the immune system’s microglia cells. This process helps reduce amyloid buildup and may slow the neurodegenerative process associated with Alzheimer’s disease. In clinical trials, Kisunla slowed cognitive and functional decline by approximately 20–35% compared to placebo in patients with lower to moderate tau levels.
Kisunla is prescribed to treat:
Early symptomatic Alzheimer’s disease (MCI or mild dementia due to Alzheimer’s)
Patients with confirmed amyloid-β pathology (via imaging or diagnostic testing)
Kisunla is not a cure for Alzheimer’s, but it is designed to slow further cognitive and functional decline.
Administration: Kisunla is administered by intravenous (IV) infusion under supervision in a healthcare setting.
Dosage and Frequency:
Initial Dose: 700 mg once every 4 weeks for the first three infusions
Maintenance Dose: 1,400 mg every 4 weeks thereafter
Treatment Duration: Therapy may be discontinued once amyloid plaques are cleared on imaging
Side Effects of Kisunla
As with other anti-amyloid treatments, Kisunla can cause amyloid-related imaging abnormalities (ARIA), which may include brain swelling (ARIA-E) or microhemorrhages (ARIA-H).
Common Side Effects:
Headache
Infusion reactions (flushing, chills, nausea)
ARIA (often without symptoms)
Serious Side Effects:
Symptomatic ARIA (neurologic changes, confusion, vision issues)
Intracerebral hemorrhage (rare)
Increased ARIA risk in ApoE ε4 homozygotes — genetic testing is recommended before starting treatment
How to Prepare for Kisunla Infusions
Before beginning Kisunla therapy, patients should:
Complete a baseline brain MRI to assess for any pre-existing brain changes
Undergo genetic testing for ApoE ε4 to evaluate ARIA risk
Confirm amyloid-β pathology via PET scan or cerebrospinal fluid testing
Discuss all current medications and health conditions with their provider
How to Access Kisunla Treatment
Treatment must be prescribed and administered by a qualified healthcare provider experienced in Alzheimer’s care
Ongoing MRI monitoring is required during treatment
Insurance coverage often requires prior authorization and documentation of eligibility, including confirmed amyloid-β pathology
The Importance of Kisunla in Alzheimer’s Care
Kisunla represents a new generation of disease-modifying therapies for Alzheimer’s disease. Rather than simply addressing symptoms, it targets the underlying amyloid pathology believed to drive disease progression. By enabling treatment discontinuation once amyloid plaques are cleared, Kisunla offers a potentially more cost-effective and lower-exposure option compared to continuous therapies — giving hope to patients and families facing early-stage Alzheimer’s disease.
Infuse One Price
Financial aid for complete treatment
Extra Cost
Commercial Insurance
Medicare
Medicare
Advantage
